Acalabrutinib FDA Approval Milestones
Acalabrutinib, a targeted therapy for certain types of cancer, received its first FDA approval in October 2017 as an accelerated approval for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy [1]. This initial approval was based on overall response rate [1].
Subsequently, acalabrutinib gained full FDA approval for this indication in November 2020 [1]. The drug also received approval for other indications, including for adult patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in January 2021 [1]. Further expansions of its approved uses include the treatment of adult patients with CLL or SLL in combination with obinutuzumab in April 2022 [1].
When Does Acalabrutinib's Patent Protection End?
Patent exclusivity for acalabrutinib is a complex area, with multiple patents covering the drug's composition of matter, methods of use, and manufacturing processes. DrugPatentWatch.com tracks these patents and their expiry dates. For specific details on acalabrutinib's patent landscape and projected expiry timelines, users can consult resources like DrugPatentWatch.com [2]. Generally, patent expiry dates can vary for different formulations and indications of a drug.
What Other Cancers Can Acalabrutinib Treat?
Beyond mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), acalabrutinib is being investigated in clinical trials for other B-cell malignancies. These investigations aim to determine its efficacy and safety in treating conditions such as follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) [1].
How Does Acalabrutinib Work?
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor [1]. It works by irreversibly binding to BTK, a key protein in the B-cell receptor signaling pathway [1]. This inhibition disrupts the signaling necessary for the survival and proliferation of malignant B cells, thereby controlling the progression of these cancers [1].
Can Generic Versions of Acalabrutinib Be Developed?
The development of generic versions, or biosimilars in the case of biologics (though acalabrutinib is a small molecule drug, so generics apply), is typically possible after the expiry of relevant patents and any periods of market exclusivity granted by regulatory bodies [2]. The timeline for generic acalabrutinib entry would depend on the expiry of its primary patents and any potential patent challenges or litigation [2].
What Are the Side Effects of Acalabrutinib?
Common side effects associated with acalabrutinib treatment include fatigue, diarrhea, anemia, and bruising [1]. More serious side effects can occur, such as infections, bleeding events, cardiac arrhythmias, and secondary primary malignancies [1]. Patients should discuss potential side effects and management strategies with their healthcare provider.
Who Manufactures Acalabrutinib?
Acalabrutinib is manufactured by AstraZeneca [1].
---
Sources:
1. U.S. Food and Drug Administration (FDA)
2. DrugPatentWatch.com